Cardiology

Fast Track designation comes about a month after dapagliflozin received another Fast Track designation for delaying the progression of renal failure and prevent CV and renal death in patients with chronic kidney disease

How new dapagliflozin findings from ESC 2019 and HFSA 2019 shape our understanding of the SGLT-2 inhibitor's benefit.

Investigators present data during the HFSA meeting on how different types of meals at different time impact the body’s circadian rhythm.

Emerging mechanical therapy options have given life to a field which has gone under severe recharacterization in an era of increased obesity.

Hospital costs, length of stay, and even mortality were shown to be significantly cut in TAVR patients with comorbid heart failrue than those without, new data shows.

By doubling the recommended weekly dialysis, patients see a number of benefits, including a reduction in blood pressure and improvements in cardiovascular vibration.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.

Despite an embrace of greater patient populations by the FDA, cardiovascular research into stem cell therapy has been slow and burdened.

A six-month regimen of the oral therapy showed patients with out-of-proportion PH improved their six-minute walking test scores.

How do a pair of burgeoning agents influence endocrinology and renal outcomes in cardiovascular care?

In a presentation at the annual HFSA meeting, investigators compare the level of care and ultimate outcomes treating heart failure patients for cardiologists and non-cardiologists.

As safety and efficacy programs advance, clinicians consider the investigative therapy's potential in cardiology.

At the annual HFSA meeting, investigators explain how obstructed sleep apnea and central sleep apnea drive cardiovascular disease.

A new study shows just more than 55% of all heart failure-based trials on ClinicalTrials.gov have shared results since 2008.

Investigators report findings no significant associations between BP control and cardiovascular mortality in patients from differing race/ethnicities with HF, stratified by hypertension treatment.

A post hoc analysis of TOPCAT shows older patients with HFpEF report consistent efficacy with spironolactone, but worsening safety outcomes.

Lab tests confirm low levels of NDMA in the popular heart burn medication, sparking a probe in the US and Europe.

Prior to the start of HFSA, Dr. Murray dives through how the extensive history of heart failure research has lead to today's greatest cardiovascular breakthroughs.

A recent analysis that included data on 284 patients found that more than 80% of patients with resistant hypertension also had obstructive sleep apnea.

Through clinical trials, investigators find that SGLT2 inhibitors are not only safe, but have several cardiovascular benefits.

The scope and scale of kidney disease is on the rise—much like its most commonly associated conditions.

A recent study found the lifetime risk of peripheral artery disease in black patients was around 30% while Hispanic and white patients had prevalence rates around 20%.

A recent study from investigators at the Rutgers Robert Wood Medical School found that rates of hypertension among pregnant women have spiked between 1970 and 2010.

A study from the University of California San Francisco found that patients with HIV were at an 80% increased risk of suffering from atrial fibrillation.

Dhruv Kazi, MD, of Beth Israel Deaconess Medical Center, discusses a recent study he led into the cost-effectiveness of polypill and why we do not see the approach applied to cardiovascular disease in the US.